Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate

Bibliography

• Uribarri J. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus Intake. Semin Dial 2007;20(4):295-301
   PubMed Web of Science ®Google Scholar
• Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006;91:3144-9
   PubMed Web of Science ®Google Scholar
• Allen LH, Wood RJ. Calcium and phosphorus in modern nutrition. In: Shils ME, Olson JA, Shike M, edtiors Health and disease. 8th edition. Lea & Febiger; Philadelphia: 1994. p. 144-63
   Google Scholar
• Ramirez JA, Emmett M, White MG, The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int 1986;30:753-95
   PubMed Web of Science ®Google Scholar
• Tenenhouse HS. Regulation of phosphate homeostasis by the tyoe IIaNa/phosphate cotransporter. Annu Rev Nutr 2005;25:197-2146
   PubMed Web of Science ®Google Scholar
• Bernd TJ, Schiavi S, Kumar R, “Phosphatonins” and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 2005;189:F1170-F11827
   Google Scholar
• Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008;118:3820-88
   PubMed Web of Science ®Google Scholar
• Isakova T, Gutierrez O, Shah A, Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 2008;19:615-239
   PubMed Web of Science ®Google Scholar
• Ito N, Fukumoto S, Takeuchi Y, Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 2007;25:419-2210
   PubMedGoogle Scholar
• Torres PU, Prie' D, Molina Bletry V, Klotho: an antiaging protein involved in mineral and vitamin D metabolism. Kidney Int 2007;71:730-7
   PubMed Web of Science ®Google Scholar
• Levin A, Bakris GL, Molitch M, Prevalence of abnormal serum vitamin D, PTH, calcium,and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-8
   PubMed Web of Science ®Google Scholar
• Isakova T, Wahl P, Vargas GS, Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79(12):1370-813
   PubMed Web of Science ®Google Scholar
• Martin KJ, Gonzalez EA. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what Is normal, when to start, and how to treat? Clin J Am Soc Nephrol 2011;6:440-6
   PubMed Web of Science ®Google Scholar
• Gonzalez-Parra E, Gonzalez-Casaus ML, Gala A, Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephron Dial Transplant 2011;0:1-5
   Google Scholar
• Oliveira RB, Cancela ALE, Graciolli FG, Early control of PTH and FGF23 in normophosphatemic CKD Patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010;5:286-91
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Di Micco L, Torraca S, Acute effects of very-low-protein diet on FGF23 levels: a randomized study. Clin J Am Soc Nephrol 2012;7(4):581-7
   PubMed Web of Science ®Google Scholar
• Kuhlmann M. Phosphate Elimination in modalities of hemodialysis and peritoneal dialysis. Blood Purif 2010;29:137-44
   PubMed Web of Science ®Google Scholar
• Gotch FA, Panlilio F, Sergeyeva O, A kinetic model of inorganic phosphorus mass balance in hemodialysis therapy. Blood Purif 2003;21:51-719
   PubMed Web of Science ®Google Scholar
• Al-Hejaili F, Kortas C, Leitch R, Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J Am Soc Nephrol 2003;14:2322-820
   PubMedGoogle Scholar
• Minutolo R, Bellizzi V, Cioffi M, Postdialytic rebound of serum phosphorus: pathogenetic and clinical insights. J Am Soc Nephrol 2002;13:1046-54
   PubMedGoogle Scholar
• KDOQI Clinical Practice Guidelines and Clinical Practice. Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007;49:S12-S154
   PubMedGoogle Scholar
• Block GA, Klassen PS, Lazarus JM, Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kuwae N, Regidor DL, Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-80
   PubMed Web of Science ®Google Scholar
• Tentori F, Blayney MJ, Albert JM, Mortality risk for dialysis patients with different levelsofserum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-30
   PubMed Web of Science ®Google Scholar
• KDIGO. Treatment of CKD–MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney Int 2009;76(Suppl 113):S50-S9
   Google Scholar
• Isakova T, Gutierrez OM, Chang Y, Phosphorus Binders and Survival on Hemodialysis. J Am Soc Nephrol 2009;20:388-96
   PubMed Web of Science ®Google Scholar
• Fouque D, Pelletier S, Mafra D, Chauveau P. Nutrition and chronic kidney disease. Kidney Int 2011;80:348-57
   PubMed Web of Science ®Google Scholar
• Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev 2009(3):CD001892
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Gutekunst L, Mehrotra R, Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5:519-30
   PubMed Web of Science ®Google Scholar
• Noori N, Kalantar-Zadeh K, Kovesdy CP, Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. Clin J Am Soc Nephrol 2010;5:683-9231
   PubMed Web of Science ®Google Scholar
• Shinaberger CS, Greenland S, Kopple JD, Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease. Am J Clin Nutr 2008;88:1511-18
   PubMed Web of Science ®Google Scholar
• Fouque D, McKenzie J, de Mutsert R, Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life. Nephrol Dial Transplant 2008;23:2902-1033
   PubMed Web of Science ®Google Scholar
• Isakova T, Gutierrez OM, Wolf M. The authors reply to “Proposed controlled trials of phosphate reduction in CKD: which whey should we go?”. Kidney Int 2010;77:930
   PubMedGoogle Scholar
• Goodman WG, Goldin J, Kuizon BD, Coronary-artery calcification in young adults with end stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Donjie F, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;352:1296-305
   Google Scholar
• Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in cronic kidney disease. Kidney Int 2005;68:429-36
   PubMed Web of Science ®Google Scholar
• Jono S, McKee MD, Murry CE, Phosphateregulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-17
   PubMed Web of Science ®Google Scholar
• Linefsky JP, O'Brien KD, Katz R, Association of serum phosphate levels with aortic valve sclerosis and annular calcification The Cardiovascular Health Study. J Am Coll Cardiol 2011;58:291-739
   PubMed Web of Science ®Google Scholar
• Russo D, Palmiero G, De Blasio AP, Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2004;44:1024-103040
   PubMed Web of Science ®Google Scholar
• Sumida Y, Nakayama M, Nagata M, Carotid artery cacification and atherosclerosis at the initiation of hemodialysis in patients with end-stage renal disease. Clin Nephrol 2010;73(5):360-9
   PubMed Web of Science ®Google Scholar
• Shimada T, Kakitani M, Yamazaki Y, Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-842
   PubMed Web of Science ®Google Scholar
• Sitara D, Razzaque MS, St-Arnaud R, Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 2006;169:2161-70. 43
   PubMed Web of Science ®Google Scholar
• Stubbs JR, Liu S, Tang W, Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007;18:2116-444
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Brandenburg V. Warfarin: to use or not to use in chronic kidney disease patients? J Nephrol 2010;23:648-52
   PubMedGoogle Scholar
• Cozzolino M, Mazzaferro S, Brandenburg V. The treatment of hyperphosphataemia in CKD:calcium-based or calcium-free phosphate binders? Nephrol Dial Transplant 2011;26:402-7
   PubMed Web of Science ®Google Scholar
• Raggi P, James G, Burke SK, Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005;20:764-72
   PubMedGoogle Scholar
• London GM, Marty C, Marchais SJ, Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15:1943-51
   PubMed Web of Science ®Google Scholar
• Moe SM. Vascular calcification and renal osteodistrophy relationship in chronic kidney disease. Eur J Clin Invest 2006;36(Suppl 2):51-62
   PubMedGoogle Scholar
• Raggi P, Bellasi A, Ferramosca E, Pulse wave velocity is inversely related to vertebral bone density in demodialysis patients. Hypertension 2007;49:1278-84
   PubMedGoogle Scholar
• Galassi A, Spiegel DM, Bellasi A, Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrol Dial Transplant 2006;21:3215-2251
   PubMed Web of Science ®Google Scholar
• Block GA, Raggi P, Bellasi A, Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41
   PubMed Web of Science ®Google Scholar
• Dhingra R, Sullivan LM, Fox CS, Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879-85
   PubMed Web of Science ®Google Scholar
• Foley RN, Collins AJ, Ishani A, Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2008;156:556-6354
   PubMed Web of Science ®Google Scholar
• Tonelli M, Sacks F, Pteffer M. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-33
   PubMed Web of Science ®Google Scholar
• Bellasi A, Mandreoli M, Baldrati L, Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol 2011;6:883-91
   PubMed Web of Science ®Google Scholar
• Zoccali C, Ruggenenti P, Perna A, Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibinotion. J Am Soc Nephrol 2011;10:1923-30
   Google Scholar
• Ketteler M, Peterman AT. Phosphate and FGF23 in early CKD: on how to tackle an invisible foe. Nephrol Dial Transplant 2011;26;2430-2
   PubMedGoogle Scholar
• Wolf MS. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010;21:1427-35
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Galassi A, Apetrii M, Covic A. What would we like to know, and what do we not know about fibroblast growth factor 23? J Nephrol 2011;24(6):696-70660
   PubMedGoogle Scholar
• Gutierrez O, Januzzi J, Isakova T, Fibroblast growth factor-23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009;119:2545-5261
   PubMed Web of Science ®Google Scholar
• Nasrallah MM, El-Shehaby A, Salem MM, Fibroblast growth factor 23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 2010;25:2679-8562
   PubMed Web of Science ®Google Scholar
• Nakano C, Hamano T, Fujii N, Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone 2012;50:1266-7463
   PubMedGoogle Scholar
• Fleisher D, Kollerits B, Neyer U, Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) study. J Am Soc Nephrol 2007;18:2601-864
   Google Scholar
• Gutierrez O, Mannstadt M, Isakova T, Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359(6):584-92
   PubMed Web of Science ®Google Scholar
• Razzaque MS. Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol Dial Transplant 2009;24:4-766
   PubMedGoogle Scholar
• Faul C, Amaral A, Oskouel B, FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121(11):4393-40867
   PubMed Web of Science ®Google Scholar
• Voigt M, Fischer DC, Rimpau M, Fibroblast growth factor (FGF)-23 and fetuin-A in calcified carotid atheroma. Histopathology 2010;56:775-868
   PubMed Web of Science ®Google Scholar
• Shalloub V, Shatzen EM, Davis J, FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality J Clin Invest. 2012;122(7):2543-53
   Google Scholar
• Isakova T, Gutierrez OM, Wolf M. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int 2009;76:705-16
   PubMedGoogle Scholar
• Wesseling-Perry K, Pereira RC, Sahney S, Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2011;79:112-19
   PubMed Web of Science ®Google Scholar
• Hansen D, Rasmussen K, Pedersen SM, Changes in fibroblast growth factor 23 duringtreatment of secondary hyperparathyoroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant 2011;0:1-6
   Google Scholar
• Lopes AA, Tong L, Thumma J, Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012;60(1):90-101
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Palmer SC, Craig JC, Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;54:619-37
   PubMed Web of Science ®Google Scholar
• Russo D, Miranda I, Ruocco C, The progression of coronary artery calcification in pre-dialysis patients on calcium carbonate or sevelamer. Kidney Int 2007;72:1255-61
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012;7(3):487-93
   PubMed Web of Science ®Google Scholar
• Block GA, Wheeler DC, Persky MS, Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012;23:1407-15
   PubMed Web of Science ®Google Scholar
• Drueke TB, Massy ZA. Phosphate binders in CKD: bad news or good news? J Am Soc Nephrol 2012;23(8):1277-80
   PubMedGoogle Scholar
• Bostom AG. Binder blinders-Niacin of omission? Am J Kidney Dis 2010;55(4):628-30
   PubMedGoogle Scholar
• Eto N, Myiata Y, Ohno H, Nicotinamide prevents the development of hyperphosphatemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenin-induced renal failure. Nephrol Dial Transplant 2005;20:1378-84
   PubMed Web of Science ®Google Scholar
• Berndt TJ, Pfeifer J, Knox F, Nicotinamide restores phosphaturic effect of PTH and calcitonin in phosphate deprivation. Am J Physiol 1982;242:F447-2
   Google Scholar
• Maccubin D, Tipping D, Kuznetsova O, Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol 2010;5:582-9
   PubMedGoogle Scholar
• Ix JH, Ganjoo P, Tipping D, Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dislipidemic CKD stage 3 patients. Am J Kidney Dis 2011;57(6):963-5
   PubMedGoogle Scholar
• Cheng S, Young DO, Huang Y, A randomized, double-blind, placebo-controlled trial of niacinamide for rediction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1131-8
   PubMed Web of Science ®Google Scholar
• Young DO, Cheng S, Delmez A, Coyne DW. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int 2009;29:562-7
   PubMed Web of Science ®Google Scholar
• Yadav R, France M, Younis N, Extended release niacin with laropiprant: a review on efficacy, clinical relevance and safety. Expert Opin Pharmacother 2012;13(9):1345-629
   PubMed Web of Science ®Google Scholar
• Sampathkumar K, Sooraj Y, Mahaldar AR, Comparative efficiency of low dose nicotinic acid and lanthanum in lowering the phosphorus levels in hemodialysis patients [S-PO-0327]. World Congress of Nephrology; 2007
   Google Scholar
• Shahapuni I, Rahmouni K, Arrar B, Greater cost effectiveness of nicotinamide compared with that of sevelamer for controlling hyperphosphatemia in dialysis patients [S-PO-0311]. World Congress of Nephrolgy; 2007
   Google Scholar
• Daugirdas JT, William FF, Emmett M, The phosphate binder equivalent dose. Semin Dial 2011;24(1):41-9
   PubMed Web of Science ®Google Scholar
• De Freitas D, Donne RL, Hutchinson AJ. Lanthanum carbonate – a first line phosphate binder? Semin Dial 2007;20(4):325-890
   PubMedGoogle Scholar
• Martin P, Wang P, Robinson A, Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study. Am J Kidney Dis 2011;57(5):700-6
   PubMedGoogle Scholar
• Sprague SM, Abboud H, Qiu P, Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009;4:178-8592
   PubMed Web of Science ®Google Scholar
• Sprague SM, Ross EA, Nath SD, Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol 2009;72(4):252-893
   PubMed Web of Science ®Google Scholar
• How PP, Anattiwong P, Mason DL, Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients. Hemodial Int 2011;15:95-994
   PubMedGoogle Scholar
• Noto L. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders. J Renal Nutr 2011;21(3):277-89
   PubMedGoogle Scholar
• Chan WL, Rounsley K, Chapman E, Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders. J Renal Nutr 2010;20(4):270-796
   PubMedGoogle Scholar
• Hutchinson A, Laville M. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant 2008;23:3677-84
   PubMedGoogle Scholar
• Goto S, Komaba H, Morivaki K, Clinical efficacy and cost-effectiveness of lanthanum carbonate as-second line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol 2011;6:1375-84
   PubMed Web of Science ®Google Scholar
• Park H, Rascati KL, Keith MS, Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with End-Stage-Renal-Disease: a US payer perspective. Value Health 2012;14:1002-9
   Google Scholar
• Malluche HH, Maward H, Monier-Fraugere MC. Effects of treatment of renal odteodistrophy on bone histology. Clin J Am Soc Nephrol 2008;3:S157-63
   Google Scholar
• NIkolov IG, Joki N, Nguyen-Koa T, Lanthanum carbonate, like sevalmer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transplant 2012;27:505-13
   PubMed Web of Science ®Google Scholar
• Carrillo-Lopez N, Fernandez-Martin JL, Alvarez-Hernandez D, Lanthanum activates calcium-sensing receptor and enhances sensitivity to calcium. Nephrol Dial Transplant 2010;25:2930-79102
   PubMedGoogle Scholar
• Ivanovski O, Nikolov IG, Joki N, The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis 2009;205:55-62103
   PubMedGoogle Scholar
• Ciceri P, Volpi E, Brenna I, The combination of lanthanum chloride and the calcimimetic calindol delays the progression of vascular smooth muscle cells calcification. Biochem Biophys Res Commun 2012;418:770-3
   PubMedGoogle Scholar
• Zhou YB, Jin SJ, Cai Y, Lanthanum acetate inhibits vascular calcification induced by vitamin D3 plus nicotine in rats. Exp Biol Med (Maywood) 2009;234:908-17105
   PubMedGoogle Scholar
• Toussaint ND, Lau KK, Polkinghorne KR, Attenuation of aortic calcification withlanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology 2011;16:290-8
   PubMed Web of Science ®Google Scholar
• Kalil RS, Flanignan M, Stanford W, Dissociation between progression of coronary artery calcification and endothelila function in hemodialysis patients: a prospective pilot study. Clin Nephrol 2012;78(1):1-9107
   PubMed Web of Science ®Google Scholar
• Chan M, Yevzlin AS, Hinshaw M, Calciphylaxis responsive to lanthanum carbonate (FOSRENOL) therapy. Wis Med J 2008;107(7):335-8108
   Google Scholar
• Spasosvski GB, Sikole A, Gelev S, Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow up. Nephrol Dial Transplant 2006;21:2217-24
   PubMedGoogle Scholar
• Malluche HH, Siami GA, Swanepoel C, Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 2008;70(4):284-95
   PubMed Web of Science ®Google Scholar
• Shijematsu T, Tokumoto A, Nakaoka A, Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. Ther Apher Dial 2011;15(2):176-84
   PubMedGoogle Scholar
• Malluche H, Faugere M-C, Wang G, Finn WF. No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years [abstract]. J Am Soc Nephrol 2004;15:270A112
   Google Scholar
• Bervoets AR, Behets GJ, Schryvers D, Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure. Kidney Int 2009;75(4):389-98113
   PubMed Web of Science ®Google Scholar
• Muller C, Chantrel F, Failer B. A confusional state associated with use of lanthanum carbonate in a dialysis patients: a case report. Nephrol Dial Tarnsplant 2009;24(19):3245-7114
   PubMedGoogle Scholar
• Smyth MDL, Pratt RD. Comment to “A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report”. Nephrol Dial Transplant 2009;24:3898-9
   PubMedGoogle Scholar
• Altmann P, Barnett ME, Finn WF. Cognitive function in Stage 5 chronic kidney diseasepatients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate binder therapy. Kidney Int 2007;71(3):190-2
   PubMedGoogle Scholar
• Hutchison AJ, Barnett ME, Krause R, Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 2008;110:c15-23
   PubMed Web of Science ®Google Scholar